Montelukast During Pregnancy

Mechanism & Role

Montelukast is a leukotriene receptor antagonist (LTRA) that blocks cysteinyl leukotriene receptors, reducing bronchoconstriction, mucus secretion, and airway inflammation. During pregnancy its role is as:

Alternative monotherapy for mild persistent asthma
Add-on therapy (to inhaled corticosteroids) for moderate-to-severe persistent asthma

It is less effective than inhaled corticosteroids as a single agent and less effective than LABAs as add-on therapy, but remains a valid option—particularly for patients who responded well to it before conception.

Safety Profile

Teratogenicity / Congenital Anomalies

Animal studies show no teratogenicity for montelukast or zafirlukast.
A large Danish cohort study found no increased incidence of congenital abnormalities with montelukast use in pregnancy.
A 2024 systematic review and meta-analysis (Fareed et al., Congenital Anomalies) pooled available human data: risk ratio for congenital anomalies = 1.13 [95% CI 0.74–1.73, p = 0.56] — no statistically significant increase. [PMID 39129058]

Preterm Delivery & Low Birth Weight

The same meta-analysis found a significantly elevated odds ratio for preterm delivery and low birth weight: OR 1.82 [95% CI 1.35–2.45, p < 0.001]. However, this association is difficult to disentangle from confounding by indication — poorly controlled asthma itself causes preterm delivery, low birth weight, preeclampsia, and perinatal mortality.

Spontaneous Abortion

Results are inconclusive: OR 1.03 [95% CI 0.72–1.5, p = 0.86, I² = 73%]. The high heterogeneity makes interpretation unreliable.

Neurodevelopmental Outcomes

The 2024 meta-analysis found no significant risks for neurodevelopmental outcomes.

Place in Therapy (Guideline Summary)

Guideline Source	Recommendation
NAEPP Working Group on Asthma and Pregnancy	Montelukast: alternative for mild persistent; adjunct for moderate-to-severe
Creasy & Resnik's Maternal-Fetal Medicine	LTRAs provide reassuring animal data; no increase in congenital anomalies in human studies; less effective than LABAs as add-on
Murray & Nadel's Respiratory Medicine	Can be continued in patients who previously responded; large Danish cohort supports safety
Harrison's (22nd ed., 2025)	Animal studies do not suggest toxicity; can be used during pregnancy

Key principle across all guidelines: The risks of poorly controlled asthma far outweigh potential hazards of montelukast therapy.

Compared to Other Asthma Drugs in Pregnancy

Drug	Preferred Status
Inhaled budesonide / fluticasone	First-line (most data)
Inhaled albuterol (SABA)	Safe, extensive experience
LABA (salmeterol, formoterol)	Safe, use only with ICS
Montelukast / zafirlukast	Alternative / add-on; most likely compatible
Theophylline	Rarely used; requires blood-level monitoring; significant side-effect burden
Zileuton	Not recommended — limited human safety data, nonreassuring animal data
Oral corticosteroids	Use when necessary; associated with neonatal adrenal insufficiency, cleft palate, low birth weight at chronic doses

Lactation

Montelukast and zafirlukast are considered "most likely compatible" with breastfeeding. Zileuton lacks sufficient data and harm cannot be excluded.

Dermatology 2-Volume Set 5e (Bologne et al.)

Clinical Recommendations

Do not discontinue montelukast simply because of pregnancy if it is providing effective asthma control — stopping treatment risks exacerbations.
Prefer inhaled corticosteroids (budesonide or fluticasone) as first-line for persistent asthma; montelukast is an acceptable alternative if ICS are not tolerated or asthma is refractory.
Inform patients of the signal for preterm delivery and low birth weight, while contextualizing that uncontrolled asthma carries greater risk.
Monitor asthma control closely throughout pregnancy; disease course is unpredictable (~22–42% worsen, ~18–36% improve, ~40% unchanged).

Sources: Creasy & Resnik's Maternal-Fetal Medicine, pp. 1412–1413 | Murray & Nadel's Respiratory Medicine | Harrison's Principles of Internal Medicine, 22nd ed. (2025), p. 2271 | Dermatology 2-Volume Set 5e | Fareed A et al. Congenit Anom (Kyoto) 2024 Nov [PMID 39129058]

This is a shared conversation. Sign in to Orris to start your own chat.